Table 4 Comparison of CNAs by a-CGH in recurrent regions in primary tumors and metastases
Recurrent region | Detected in [number of cases / informative (%)] | ||
|---|---|---|---|
Primary tumors | Metastases | All tumors | |
No of samples | n = 18 | n = 12 | n = 30 |
Losses | |||
9pter-p13.2 | 2 / 18 (11%) | 1 / 12 (8%) | 3 / 30 (10%) |
9p13.1-11.2 | 3 / 18 (17%) | 2 / 12 (17%) | 5 / 30 17%) |
11q23.1-qter | 4 / 18 (22%) | 3 / 12 (25%) | 7 / 30 (23%) |
13q14.11-21.32 | 2 / 18 (11%) | 1 / 12 (8%) | 3 / 30 (10%) |
13q33.1 | 2 / 18 (11%) | 1 / 12 (8%) | 3 / 30 (10%) |
16q12.2-qter | 1 / 18 (6%) | 4 / 12 (33%) | 5 / 30 (17%) |
18pter-11.21 | 12 / 18 (67%) | 8 / 12 (67%) | 20 / 30 (67%) |
18q12.1-21.31 | 10 / 18 (56%) | 8 / 12 (67%) | 18 / 30 (60%) |
Gains | |||
4pter-qter | 4 / 18 (22%) | 4 / 12 (%) | 8 / 30 (27%) |
5pter-qter | 4 / 18 (22%) | 3 / 12 (25%) | 7 / 30 (23%) |
7p22.3 | 1 / 18 (6%) | 2 / 12 (17%) | 3 / 30 (10%) |
7p22.2-22.1 | 1 / 18 (6%) | 2 / 12 (17%) | 3 / 30 (10%) |
7q22.1 | 1 / 18 (6%) | 2 / 12 (17%) | 3 / 30 (10%) |
7q22.3-qter | 1 / 18 (6%) | 3 / 12 (25%) | 4 / 30 (13%) |
14q11.2 | 4 / 18 (22%) | 5 / 12 (42%) | 9 / 30 (30%) |
14q32.2-32.31 | 3 / 18 (17%) | 3 / 12 (25%) | 6 / 30 (20%) |
20pter-p11.21 | 4 / 18 (22%) | 4 / 12 (33%) | 8 / 30 (27%) |
20q11.1-11.21 | 5 / 18 (28%) | 2 / 12 (17%) | 7 / 30 (23%) |
20q12-qter | 6 / 18 (33%) | 5 / 12 (42%) | 11 / 30 (37%) |